
Peter Bell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4990858/publications.pdf Version: 2024-02-01



DETED REI

#	Article	IF	CITATIONS
1	Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Human Gene Therapy, 2018, 29, 285-298.	2.7	543
2	A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nature Biotechnology, 2016, 34, 334-338.	17.5	476
3	The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Molecular Therapy, 2018, 26, 664-668.	8.2	300
4	The GPI-Linked Protein LY6A Drives AAV-PHP.B Transport across the Blood-Brain Barrier. Molecular Therapy, 2019, 27, 912-921.	8.2	158
5	Analysis of Tumors Arising in Male B6C3F1 Mice with and without AAV Vector Delivery to Liver. Molecular Therapy, 2006, 14, 34-44.	8.2	137
6	No Evidence for Tumorigenesis of AAV Vectors in a Large-Scale Study in Mice. Molecular Therapy, 2005, 12, 299-306.	8.2	103
7	MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates. Science Translational Medicine, 2020, 12, .	12.4	96
8	Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol. Nature Biotechnology, 2018, 36, 717-725.	17.5	95
9	Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Molecular Therapy, 2015, 23, 1877-1887.	8.2	94
10	Evaluation of Intrathecal Routes of Administration for Adeno-Associated Viral Vectors in Large Animals. Human Gene Therapy, 2018, 29, 15-24.	2.7	92
11	Intrathecal Gene Therapy Corrects CNS Pathology in a Feline Model of Mucopolysaccharidosis I. Molecular Therapy, 2014, 22, 2018-2027.	8.2	89
12	Adeno-Associated Virus-Mediated Gene Transfer to Nonhuman Primate Liver Can Elicit Destructive Transgene-Specific T Cell Responses. Human Gene Therapy, 2009, 20, 930-942.	2.7	88
13	Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14051.	4.1	84
14	Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques. Molecular Therapy - Methods and Clinical Development, 2018, 10, 79-88.	4.1	79
15	Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates. Molecular Therapy, 2015, 23, 1298-1307.	8.2	72
16	Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII. Molecular Therapy, 2016, 24, 206-216.	8.2	70
17	Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques. Molecular Therapy - Methods and Clinical Development, 2018, 10, 68-78.	4.1	60
18	Safe and Sustained Expression of Human Iduronidase After Intrathecal Administration of Adeno-Associated Virus Serotype 9 in Infant Rhesus Monkeys. Human Gene Therapy, 2019, 30, 957-966.	2.7	60

Peter Bell

#	Article	IF	CITATIONS
19	Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primates. Molecular Genetics and Metabolism, 2011, 104, 395-403.	1.1	58
20	Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model. Nature Communications, 2015, 6, 7339.	12.8	51
21	AAV8 Induces Tolerance in Murine Muscle as a Result of Poor APC Transduction, T Cell Exhaustion, and Minimal MHCI Upregulation on Target Cells. Molecular Therapy, 2014, 22, 28-41.	8.2	50
22	Intramuscular Injection of AAV8 in Mice and Macaques Is Associated with Substantial Hepatic Targeting and Transgene Expression. PLoS ONE, 2014, 9, e112268.	2.5	47
23	Non-Clinical Study Examining AAV8.TBG.hLDLR Vector-Associated Toxicity in Chow-Fed Wild-Type and LDLR ^{+/â^²} Rhesus Macaques. Human Gene Therapy Clinical Development, 2017, 28, 39-50.	3.1	46
24	A mutation-independent CRISPR-Cas9–mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency. Science Advances, 2020, 6, eaax5701.	10.3	44
25	Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14894-14899.	7.1	42
26	Long-term stable reduction of low-density lipoprotein in nonhuman primates following inÂvivo genome editing of PCSK9. Molecular Therapy, 2021, 29, 2019-2029.	8.2	42
27	AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice. Molecular Genetics and Metabolism, 2017, 120, 299-305.	1.1	39
28	Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice. Human Gene Therapy, 2016, 27, 906-915.	2.7	36
29	Evaluation of Adeno-Associated Viral Vectors for Liver-Directed Gene Transfer in Dogs. Human Gene Therapy, 2011, 22, 985-997.	2.7	35
30	Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model. Molecular Genetics and Metabolism, 2016, 119, 124-130.	1.1	34
31	Nonclinical Pharmacology/Toxicology Study of AAV8.TBG.mLDLR and AAV8.TBG.hLDLR in a Mouse Model of Homozygous Familial Hypercholesterolemia. Human Gene Therapy Clinical Development, 2017, 28, 28-38.	3.1	33
32	Translational Feasibility of Lumbar Puncture for Intrathecal AAV Administration. Molecular Therapy - Methods and Clinical Development, 2020, 17, 969-974.	4.1	26
33	Adenoâ€associated virus serotype 1â€based gene therapy for FTD caused by <i>GRN</i> mutations. Annals of Clinical and Translational Neurology, 2020, 7, 1843-1853.	3.7	26
34	A Comparative Analysis of Novel Fluorescent Proteins as Reporters for Gene Transfer Studies. Journal of Histochemistry and Cytochemistry, 2007, 55, 931-939.	2.5	24
35	AAV8 Gene Therapy Rescues the Newborn Phenotype of a Mouse Model of Crigler–Najjar. Human Gene Therapy, 2018, 29, 763-770.	2.7	19
36	Effects of Self-Complementarity, Codon Optimization, Transgene, and Dose on Liver Transduction with AAV8. Human Gene Therapy Methods, 2016, 27, 228-237.	2.1	15

Peter Bell

#	Article	IF	CITATIONS
37	Intrathecal Viral Vector Delivery of Trastuzumab Prevents or Inhibits Tumor Growth of Human HER2-Positive Xenografts in Mice. Cancer Research, 2018, 78, 6171-6182.	0.9	15
38	Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16079.	4.1	14
39	AAV8 Gene Therapy for Crigler-Najjar Syndrome in Macaques Elicited Transgene T Cell Responses That Are Resident to the Liver. Molecular Therapy - Methods and Clinical Development, 2018, 11, 191-201.	4.1	14
40	A Gene Therapy Approach to Improve Copper Metabolism and Prevent Liver Damage in a Mouse Model of Wilson Disease. Human Gene Therapy Clinical Development, 2019, 30, 29-39.	3.1	14
41	Developing a second-generation clinical candidate AAV vector for gene therapy of familial hypercholesterolemia. Molecular Therapy - Methods and Clinical Development, 2021, 22, 1-10.	4.1	14
42	Determining the Minimally Effective Dose of a Clinical Candidate AAV Vector in a Mouse Model of Crigler-Najjar Syndrome. Molecular Therapy - Methods and Clinical Development, 2018, 10, 237-244.	4.1	10
43	Prednisolone reduces the interferon response to AAV in cynomolgus macaques and may increase liver gene expression. Molecular Therapy - Methods and Clinical Development, 2022, 24, 292-305.	4.1	10
44	Crispr/Cas9-Mediated In Vivo Gene Targeting Corrects Haemostasis in Newborn and Adult FIX-KO Mice. Blood, 2016, 128, 1174-1174.	1.4	9
45	Motor Neuron Transduction After Intracisternal Delivery of AAV9 in a Cynomolgus Macaque. Human Gene Therapy Methods, 2015, 26, 43-44.	2.1	6
46	Abnormal polyamine metabolism is unique to the neuropathic forms of MPS: potential for biomarker development and insight into pathogenesis. Human Molecular Genetics, 2017, 26, 3837-3849.	2.9	5
47	Strategies for Selection of AAV Vectors for Administration to Liver: Studies in Nonhuman Primates. Blood, 2016, 128, 2316-2316.	1.4	1
48	Formation of Newly Synthesized Adeno-Associated Virus Capsids in the Cell Nucleus. Human Gene Therapy Methods, 2014, 25, 179-180.	2.1	0
49	Preparation of Nonhuman Primate Eyes for Histological Evaluation After Retinal Gene Transfer. Human Gene Therapy Methods, 2018, 29, 115-123.	2.1	0